Radiance
Irvine, California firm receives a CE Mark for its RDX radioactive balloon brachytherapy device for treatment of de novo and restenotic coronary lesions. The RDX will be marketed to a few key customers, and then, following a formal launch at the Congress of the Society of Cardiology in Stockholm, Sweden Sept. 1-5, 2001, a widespread launch will start this fall. Meanwhile, Radiance expects to complete enrollment in the 480-patient BRITE II pivotal U.S. trial of the RDX by January 2002. Last January, Radiance began BRITE-SVG, a worldwide 50-patient Phase I trial of the RDX in saphenous vein grafts and in May began enrolling patients in RAPID, the European trial of the RDX in peripheral vessels. The company expects an IDE for a U.S. peripheral trial in the next few months
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. Representatives were left wondering if user fee programs would continue, even if reauthorized.
A seemingly humorous social media post on April Fool’s Day struck a nerve with regulatory experts, reflecting real concerns about recent actions by the US Food and Drug Administration.
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.